Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?

Regulatory Toxicology and Pharmacology

Volumn 27, Issue 1 I, 1998, Pages 47-60

  Cattley, Russell C ^a   DeLuca, John ^b   Elcombe, Cliff ^c   Fenner Crisp, Penelope ^d   Lake, Brian G ^e   Marsman, Daniel S ^f   Pastoor, Timothy A ^g   Popp, James A ^h   Robinson, Denise E ⁱ   Schwetz, A Bernard ^j   Tugwood, Jonathan ^g   Wahli, Walter ^k  

^a CIIT CENTERS FOR HEALTH RESEARCH   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^e BIBRA INTERNATIONAL   (United Kingdom)

^f PROCTER AND GAMBLE COMPANY   (United States)

^g ASTRAZENECA   (United Kingdom)

^h Sanofi Synthelabo Research   (United States)

ⁱ International Life Sciences Institute   (United States)

^j NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^k UNIVERSITY OF LAUSANNE   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR;

CELL PROLIFERATION; CHEMICAL CARCINOGENESIS; HUMAN; LIVER CARCINOGENESIS; LIVER CARCINOMA; PEROXISOME; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

RODENTIA;

EID: 0031838516     PISSN: 02732300     EISSN: None     Source Type: Journal    
DOI: 10.1006/rtph.1997.1163     Document Type: Article

References (95)

1. Ashby, J., Brady, A., Elcombe, C. R., Elliott, B. M., Ishamael, J., Odum, J., Tugwood, J. D., Kettle, S., and Purchase, L. F. H. (1994). Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum. Exp. Toxicol. 13(Suppl. 2), S1-S117.
2. Bardot, O., Aldridge, T. C., Latruffe, N., and Green, S. (1993). PPARRXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene. Biochem. Biophys. Res. Commun. 193, 37-45.
3. Barrass, N. C., Price, R. J., Lake, B. G., and Orton, T. C. (1993). Comparison of the acute and chronic mitogenic effects of the peroxisome proliferator methylclofenapate and clofibric acid in rat liver. Carcinogenesis 14(7), 1451-1456.
4. Bentley, P., Calder, I., Elcombe, C., Grasso, P., Stringer, D., and Wiegand, H. J. (1993). Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem. Toxicol. 31, 857-907.
5. Biegel, L. B., Liu, R. C. M., Hurt, M. E., and Cook, J. C. (1995). Effects of ammonium perfluorooctanoate on leydig cell function: In vitro, in vivo, and ex vivo studies. Toxicol. Appl. Pharmacol. 134(1), 18-25.
6. Blumcke, S., Schwartzkopff, W., Lobeck, H., Edmondson, N. A., Prentice, D. E., and Blane, G. F. (1983). Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients. Atherosclerosis 46, 105-116.
7. Braissant, O., Foufelle, F., Scotto, D., Dauca, M., and Wahli, W. (1996). Differential expression of peroxisome proliferator-activated receptors (PPARS) - Tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology 137, 334-366.
8. Buchanan, J. R., Grizzle, T. B., Buckley Kedderis, L., Collins, B. J., Goehl, T. J., Handy, R. W., and Marsman, D. S. (1995). Toxicokinetics of gemfibrozil in rats, mice and hamsters. Int. Toxicologist VII, 47 P-14.
9. Bursch, W., Lauer, B., Timmermann-Trosiener, L, Barthel, G., Schuppler, J., and Schulte-Hermann, R. (1984). Controlled death (apoptosis) of normal and putative preneoplastic cells in rat liver following withdrawal of tumor promoters. Carcinogenesis 5(4), 453-458.
10. Cattley, R. C., and Glover, S. E. (1993). Elevated 8-hydroxydeoxyguanosine in hepatic DNA of rats following exposure to peroxisome proliferator-relationship to carcinogenesis and nuclear localization. Carcinogenesis 14(12), 2495-2499.
11. Cattley, R. C., and Popp, J. A. (1989). Differences in the promoting activities of the peroxisome proliferator Wy-14,643 and phenobarbital in rat liver. Cancer Res. 49, 3246-3251.
12. Cattley, R. C., Marsman, D. S., and Popp, J. A. (1991). Age-related susceptibility to the carcinogenic effect of the peroxisome proliferation Wy-14,643 in rat liver. Carcinogenesis 12(3), 469-473.
13. 2-generation peroxisomal fatty acyl-CoA oxidase. Proc. Natl. Acad. Sci. USA 92(15), 7080-7084.
14. Cohen, A. J., and Grasso, P. (1981). Review of the hepatic response to hypolipidaemic drugs in rodents and assessment of its lexicological significance to man. Food Chem. Toxicol. 19, 585-605.
15. Collins, B. J., Buckley Kedderis, L., Grizzle, T. B., Ghoehl, T. J., Handy, R. W., and Marsman, D. S. (1995). Toxicokinetics (TK) of di-n-butylphthalate (DBF) in rats, mice and hamsters. Int. Toxicologist VII, 47-P-13.
16. Conway, J. G., Tomaszewski, K. E., Olson, M. J., et al. (1989). Relationship of oxidative damage to the hepatocarcinogenicity of the peroxisome proliferators di (2-ethylhexyl)phthalate and Wy-14,643. Carcinogenesis 3, 513-519.
17. Corton, J. C., Bocos, C., Moreno, E. S., et al. (1996). Rat 17β-hydroxysteroid dehydrogenase type IV is a novel peroxisome proliferator-inducible gene. Mol. Pharmacol. 50, 1157-1166.
18. De La Iglesia, F. A., Lewis, J. E., Buchanan, R. A., Marcus, L. E., and McMahon, G. (1982). Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatment. Atherosclerosis 43, 19-37.
19. Desvergne, B., and Wahli, W. (1995). PPAR: A key factor in nutrient/ gene interactions. In Inducible Transcription (P. Baeuerle, Ed.), Vol. 1, pp. 142-176. Birkhäuser, Boston.
20. Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., and Wahli, W. (1996). The PPARα-leukotriene B4 pathway to inflammation control. Nature 384, 39-43.
21. Dreyer, D., Krey, G., Keller, H., Givel, F., Helftenbein, G., and Wahli, W. (1992). Control of the peroxisome beta oxidation pathway by a novel family of nuclear hormone receptors. Cell 68, 879-887.
22. Durnford, J. M., Brody, R. S., Hejtmancik, M. R., Kurtz, P. J., Renne, R. A., Gideon, K M., and Marsman, D. S. (1995). Differential enzyme inducing activity of peroxisome proliferators in the male syrian hamster. Int. Toxicologist VII, 47-P-4.
23. Eacho, P. I., Lanier, T. I., and Brodhecker, C. A. (1991). Hepatocellular DNA synthesis in rats given peroxisome proliferating agents -comparison of Wy-14,643 to clofibric acid, nafenopin and LY171883. Carcinogenesis 12(9), 1557-1561.
24. Elcombe, C. R., and Styles, J. A. (1989). Species differences in peroxisome proliferation. Toxicologist 9, 63.
25. Elcombe, C. R., Bell, D. R., Elias, E., Hasmail, S. C., and Plant, J. P. (1997). Peroxisome Proliferators: Species differences in response of primary hepatocyte cultures. Ann. N.Y. Acad. Sci. 804, 628-635.
26. Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Speigelman, B. M., and Evans, R. M. (1995). 15-Deoxy-delta(12,14)-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR-gamma. Cell 83, 803-812.
27. Giometti, C. S., Tollaksen, S. L., and Marsman, D. S. (1995). Liver protein changes in B6C3F1 mice and Syrian hamsters treated with the peroxisome proliferator Wy-14,643. Int. Toxicologist VII, 47-P-5.
28. Goel, S. K, Lalwani, N. D., and Reddy, J. K. (1986). Peroxisome proliferators and lipid peroxidation in rat liver. Cancer Res. 46,1324-1330.
29. Grasl-Kraupp, B., Huber, W., Just, W., Gibson, G., and Schulte-Hermann, R. (1993). Enhancement of peroxisomal enzymes, cytochrome p450 and DNA syntheses in putative preneoplastic foci of rat liver treated with the peroxisome proliferator nafenopin. Carcinogenesis 14(5), 1007-1012.
30. Grizzle, T. B., Buckley Kedderis, L., Collins, B. J., Goehl, T. J., Handy, R. W., and Marsman, D. S. (1995). Toxicokinetics (TK) of 2,4-dichlorophenoxyacetic acid (2,4-D) in rats, mice and hamsters. Int. Toxicologist VII, 47-P-9.
31. Hanefeld, M., Kemmer, C. H., Leonhardt, W., Kunze, K. D., Jaross, W., and Haller, H. (1980). Effects of p-chlorophenoxyisobutyric acid (CPIB) on the human liver. Atherosclerosis 36, 159-172.
32. Hertz, R., Bishara-Shieban, J., and Bar-Tana, J. (1995). Mode of action of peroxisome proliferators as hypolipidemic drugs. J. Biol. Chem. 270, 13470-13475.
33. Hong, J. T., Wilson, M. W., and Glauert, H. P. (1995). Effect of phenobarbital and the peroxisome proliferator ciprofibrate on glutamyltranspeptidase activity and leukotriene C4 concentration in cultured rat hepatocytes. J. Biochem. Toxicol. 10(5), 239-243.
34. IARC (1995). Peroxisome Proliferation and Its Role in Carcinogenesis, IARC Technical Report No. 24. IARC, Lyon, France.
35. Issemann, L, Prince, R. A., Tugwood, J. D., and Green, S. (1993). The PPAR:RXR heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J. Mol. Endocrinol. 11, 37-47.
36. James, H. H., and Roberts, R. A. (1996). Species differences in response to peroxisome proliferators correlate in vitro with induction of DNA synthesis rather than suppression of apoptosis. Carcinogenesis 17, 1623-1632.
37. Jones, P. S., Savory, R., Barratt, P., Bell, A. R., Gray, T. J. B., Jenkins, N. A., Gilbert, D. J., Copeland, N. G., and Bell, D. R. (1995). Chromosomal localisation, inducibility, tissue-specific expression and strain differences in three murine peroxisome proliferator-activated receptor genes. Ear. J. Biochem. 233, 219-226.
38. Kasai, H., Okada, Y., Nishimura, S., Rao, M. S., and Reddy, J. K. (1989). Formation of 8-hydroxydeoxyguanosine in liver DNA of rats following long-term exposure to a peroxisome proliferator. Cancer Res. 49, 2603-2605.
39. Keller, H., Dreyer, C., Medin, J., Mahfoudi, A., Ozato, K, and Wahli, W. (1993). Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc. Natl. Acad. Sci. USA 90, 2160-2164.
40. Kliewer, S. A., Umesono, K., Noonan, D. J., Hyman, R. A., and Evans, R. M. (1992). Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature 358, 771-774.
41. Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, L, Morris, D. C., and Lehmann, J. M. (1995). A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83, 813-819.
42. Kraupp-Grasl, B., Huber, W., Putz, B., Gerbracht, U., and Schulte, H. R. (1990). Tumor promotion by the peroxisome proliferator nafenopin involving a specific subtype of altered foci in rat liver. Cancer Res. 50(12), 3701-3708.
43. Lake, B. G., Kozlen, S. L., Evans, J. G., Gray, T. J. B., Young, P. J., and Gangolli, S. D. (1987). Effect of prolonged administration of clofibric acid and di-(2-ethylhexyl) phthalate of hepatic enzyme activities and lipid peroxidation in the rat. Toxicology 44, 213-228.
44. Lake, B. G., Evans, J. G., Cunninghame, M. E., and Price, R. J. (1993). Comparison of the hepatic effects of nafenopin and Wy-14,643 on peroxisome proliferation and cell replication in the rat and Syrian hamster. Environ. Health Perspect. 101(Suppl. 5), 241-248.
45. Lake, B. G. (1995a). Mechanisms of hepatocarcinogenicity of peroxisome-proliferating drugs and chemicals. Anna. Rev. Pharmacol. Toxicol. 35, 483-507.
46. Lake, B. G. (1995b). Peroxisome proliferation: Current mechanisms relating to non-genotoxic carcinogenesis. Toxicol. Lett. 82/83, 673-681.
47. Lake, B. G., Rumsby, P. C., Brown, K L., Price, R. J., and Cunninghame, M. E. (1995). Species differences in hepatic peroxisome proliferation, cell replication and transforming growth factor-β1 (TFG-β1) gene expression. Toxicologist 15, 241.
48. Lambe, K. G., and Tugwood, J. D. (1996). A human peroxisome-proliferation-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur. J. Biochem. 239, 1-7.
49. Lee, S. S. T., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., Fernandez-Salguero, P. M., Westphal, H., and Gonzalez, F. J. (1995). Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15, 3012-3022.
50. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., and Kliewer, S. A. (1995). An antidiabetic thiazolidinedione is a high affinity ligand for the nuclear receptor PPARγ. J. Biol. Chem. 270, 12953-12956.
51. Lemberger, T., Staels, B., Saladin, R., Desvergne, B., Auwerx, J., and Wahli, W. (1994). Regulation of the peroxisome proliferator-activated receptor α gene by glucocorticoids. J. Biol. Chem. 269, 24527-24530.
52. Lemberger, T., Saladin, R., Vázquez, M., Assimacopoulos, F., Staels, B., Desvergne, B., Wahli, W., and Auwerx, J. (1996). Expression of the peroxisome proliferator-activated receptor α gene is stimulated by stress and follows a diurnal rhythm. J. Biol. Chem. 271, 1764-1769.
53. Leung, L. K., and Glauert, H. P. (1996). Reduction of the concentrations of prostaglandins e-2 and f-e alpha, and thromboxane b-2 in cultured rat hepatocytes treated with the peroxisome proliferator ciprofibrate. Toxicol. Lett. 85(3), 143-149.
54. Li, Y., Glauert, H. P., and Spear, B. T. (1996). NF-κB activity is increased by the peroxisome proliferator ciprofibrate in rats. Proc. AACR 37, 160.
55. Lock, E. A., Mitchell, A. M., and Elcombe, C. R. (1989). Biochemical mechanisms of induction of hepatic peroxisome proliferation. Anna. Rev. Pharmacol. Toxicol. 29, 145-163.
56. Marsman, D. S., Cattley, R. C., Conway, J. G., and Popp, J. A. (1988). Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rats. Cancer Res. 48, 6739-6744.
57. Marsman, D. S. (1991). Peroxisome Proliferator Hepatocarcinogenesis in Rats, dissertation. University of North Carolina, Chapel Hill, NC.
58. Marsman, D. S., Goldsworthy, T. L., and Popp, J. A. (1992). Contrasting hepatocytic peroxisome proliferation, lipofuscin accumulation and cell turnover for the hepatocarcinogens Wy-14,643 and clofibric acid. Carcinogenesis 15, 1011-1017.
59. Marsman, D. S., and Barrett, J. C. (1994). Apoptosis and chemical carcinogenesis. Risk Anal. 14(3), 321-326.
60. Marsman, D. S., and Popp, J. A. (1994). Biological potential of basophilic hepatocellular foci and hepatic adenoma induced by the peroxisome proliferator, Wy-14,643. Carcinogenesis 15, 111-117.
61. Marsman, D. S., Buckley Kedderis, L., Grizzle, T. B., Collins, B. J., Handy, R. W., and Goehl, T. J. (1995). Toxicokinetics (TK) of the peroxisome proliferator Wy-14,643 in rats, mice and hamsters. Int. Toxicologist VII, 47-P-11.
62. Miller, R. T., Glover, S. E., Stewart, W. S., Corton, J. C., Popp, J. A., and Cattley, R. C. (1996). Effect on the expression of c-met, c-myc and PPAR-alpha in liver and liver tumors from rats chronically exposed to the hepatocarcinogenic peroxisome proliferator Wy-14,643. Carcinogenesis 17, 1337-1341.
63. Miller, R. T., and Cattley, R. C. (1996). Characterization of regressing peroxisome proliferator-induced hepatocellular adenomas. Proc. AACR 37, 160.
64. Miyata, K. S., Zhang, B., Marcus, S. L., Capone, J. P., and Rachubinski, R. A. (1993). Chicken ovalbumin upstream promoter transcription factor (COUP-TF) binds to a peroxisome proliferator responsive element and antagonises peroxisome proliferator mediated signalling. J. Biol. Chem. 268, 19169-19172.
65. Moody, D. E., Reddy, J. K, Lake, B. G., Popp, J. A., and Reese, D. H. (1991). Peroxisome proliferation and nongenotoxic carcinogenesis: Commentary on a symposium. Fundam. Appl. Toxicol. 16, 233-248.
66. Nemali, M. R., Usuda, N., Reddy, M. K, Oyasu, K., Hashimoto, T., Osumi, T., Rao, M. S., and Reddy, J. K. (1988). Comparison of constitutive and inducible levels of expression of peroxisomal betaoxidation and catalase genes in liver and extrahepatic tissue of rat. Cancer Res. 48, 5316-5324.
67. Nemali, M. R., Reddy, M. K, Usuda, N., Reddy, P. G., Comeau, L. D., Rao, M. S., and Reddy, J. K. (1989). Defferential induction and regulation of peroxisomal enzymes: predictive value of peroxisome proliferation in identifying certain nonmutagenic carcinogens. Toxicol. Appl. Pharmacol. 97, 72-87.
68. Orton, T. C., Adam, H. K, Bentley, M., Holloway, B., and Tucker, M. J. (1984). Clobuzarit: Species differences in the morphological and biochemical response of the liver following chronic administration. Toxicol. Appl. Pharmacol. 73, 138-151.
69. Palmer, C. N. A., Hsu, M-H., Muerhoff, A. S., Griffen, K. J., and Johnson, E. F. (1994). Interaction of the peroxisome proliferator-activated receptor α with the retinoid X receptor α unmasks a cryptic peroxisome proliferator response element that overlaps an ARP-1-binding site in the CYP4A6 promoter. J. Biol. Chem. 269, 18083-18089.
70. Parzefall, W., Erber, E., Sedivy, R., and Schulte-Hermann, R. (1991). Testing for induction of DNA synthesis in human hepatocyte primary cultures by rat liver tumor promoters. Cancer Res. 51, 1143-1147.
71. Peters, J. M., Cattley, R. C., and Gonzalez, F. J. (1997). Role of PPAR-α in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis, in press.
72. Popp, J. A., and Cattley, R. C. (1993). Peroxisome proliferators as initiators and promoters of rodent hepatocarcinogenesis. In Peroxisomes: Biology and Importance in Toxicology and Medicine (G. Gibson and B. Lake, Eds.), pp. 653-665. Taylor & Francis, London.
73. Reddy, J. K, Azarnoff, D. L., and Sirtori, C. R. (1978). Hepatic peroxisome proliferation: Induction by BR-931, a hypolipidemic analog of Wy-14,643. Arch. Int. Pharmacodyn. 234, 4-14.
74. Reddy, J. K, Sambasiva Rao, M., Azarnoff, D. L., and Sell, S. (1979). Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643), in rat and mouse liver. Cancer Res. 39, 152-158.
75. Reddy, J. K., and Lalwani, N. D. (1983). Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. Crit. Rev. Toxicol. 12, 1-58.
76. Rhodes, C., Orton, T. C., Pratt, I. S., Batten, P. L., Bratt, H., Jackson, S. J., and Elcombe, C. R. (1986). Comparative pharmacokinetics and subacute toxicity of di-(2-ethylhexyl)phthalate (DEHP) in rats and marmosets: extrapolation of effects in rodents to man. Environ. Health Perspect. 65, 299-308.
77. Roberts, R. A., Soames, A. R., Gill, J. H., James, N. H., and Wheeldon, E. B. (1995). Non-genotoxic hepatocarcinogens stimulate DNA synthesis and their withdrawal induces apoptosis, but in different hepatocyte populations. Carcinogenesis 16(8), 1693-1698.
78. Rodricks, J. V., and Turnbull, D. (1987). Interspecies difference in peroxisomes and peroxisome proliferation. Toxicol. Ind. Health 3, 197-212.
79. Sausen, P. J., Lee, D. C., Rose, M. L., and Cattley, R. C. (1995). Elevated 8-hydroxydeoxyguanosine in hepatic DNA of rats following exposure to peroxisome proliferators: Relationship to mitochondrial alterations. Carcinogenesis 16(8), 1795-1801.
80. Schmidt, A., Endo, N., Rutledge, S. J., Vogel, R., Shinar, D., and Rodan, G. A. (1992). Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol. Endocrinol. 6, 1634-1641.
81. Sher, T., Yi, H-F., McBride, O. W., and Gonzalez, F. J. (1993). cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32, 5598-5604.
82. Stott, W. T. (1988). Chemically induced proliferation of peroxisomes: Implications for risk assessment. Regul. Toxicol. Pharmacol. 8, 125-159.
83. Styles, J. A., Kelly, M., Pritchard, N. R., and Elcombe, C. R. (1988). A species comparison of acute hyperplasia induced by the peroxisome proliferator methylclofenapate: Involvement of the binucleated hepatocyte. Carcinogenesis 9, 1647-1655.
84. Styles, J. A., Kelly, M., Pritchard, N. R., and Foster, J. R. (1990). Effects produced by the non-genotoxic hepatocarcinogen methylclofenapate in dwarf mice: Peroxisome induction uncoupled from DNA synthesis and nuclearity changes. Carcinogenesis 11, 387-391.
85. Takagi, A., Sai, K., Unenura, T., Hasegawa, R., and Kurokawa, Y. (1990). Relationship between hepatic peroxisome proliferation and 8-hydroxydeoxyguanosine formation in liver DNA of rats following long-term exposure to three peroxisome proliferators: di(2-ethylhexyl) phthalate, aluminium clofibrate and simfibrate. Cancer Lett. 53, 33-38.
86. Tanaka, K, Smith, P. F., Stromberg, P. C., Eydelloth, R. S., Herold, E. G., Grossman, S. J., Frank, J. D., Hertzog, P. R., Soper, K A., and Keenan, K. P. (1992). Studies of early hepatocellular proliferation and peroxisomal proliferation in Sprague-Dawley rats treated with tumorigenic doses of clofibrate. Toxicol. Appl. Pharmacol. 116(1), 71-77.
87. Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., and Siegelman, B. M. (1994). MPPAR-gamma2: Tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8, 1224-1234.
88. Tucker, M. J., and Orton, T. C. (1995). Comparative Toxicology of Hypolipidaemic fibrates. Taylor & Francis, London.
89. Tugwood, J. D., Issemann, L, Andersen, R. G., Bundell, K. R., McPheat, W. L., and Green, S. (1992). The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking region of the rat acyl CoA oxidase gene. EMBO J. 11, 433-439.
90. Tugwood, J. D., Aldridge, T. C., Lambe, K. G., MacDonald, N., and Woodyatt, N. J. (1997). Peroxisome proliferator activated-receptor: Structures and functions. Ann. N.Y. Acad. Sci. 804, 252-265.
91. Vu-Dac, N., Schoonjans, K., Laine, B., Fruchart, J., Auwerx, J., and Staels, B. (1994). Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J. Biol. Chem. 269, 31012-31018.
92. Vu-Dac, N., Schoonjans, K., Kosyth, V., Dallongaville, J., Fruchart, J. C., Staels, B., and Auwerx, J. (1995). Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J. Clin. Invest. 96, 741-750.
93. Wada, N., Marsman, D. S., and Popp, J. A. (1992). Dose-related effects of hepatocarcinogen Wy-14,643, on peroxisomes and cell replication. Fundam. Appl. Toxicol. 18, 149-154.
94. Wilson, M. W., Lay, L. T., Chow, C. K, Tai, H. H., Robertson, L. W., and Glauert, H. P. (1995). Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid. Arch. Toxicol. 69(7), 491-497.
95. Zhang, B., Marcus, S. L., Fereydoun, G. S., Alvares, K., Reddy, J. K., Subramani, S., Rachubinski, R. A., and Capone, J. P. (1992). Identification of a peroxisome proliferator responsive element upstream of the gene encoding rat peroxisomal enoyl-CoA hydrates/3-hydroxyacyl-CoA dehydrogenase. Proc. Natl. Acad. Sci. USA 89, 7541-7545.